Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer

Annals of Surgical Oncology

Volumn 19, Issue 5, 2012, Pages 1707-1712

  Kong, Sun Young ^a,b   Han, Mi Hwa ^a   Yoo, Heon Jong ^c   Hwang, Jong Ha ^c   Lim, Myong Cheol ^c   Seo, Sang Soo ^c   Yoo, Chong Woo ^c   Kim, Jae Hoon ^d   Park, Sang Yoon ^c   Kang, Sokbom ^c  

^a National Cancer Center   (South Korea)

^b National Cancer Center ^*  (South Korea)

^c National Cancer Center   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OPERATION DURATION; OVARY CARCINOMA; PROGRESSION FREE SURVIVAL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PROTEINS; SERUM; TUMOR MARKERS, BIOLOGICAL;

EID: 84862558119     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1943-5     Document Type: Article

References (21)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30. (Pubitemid 40310185)
2. Park B, Park S, Kim TJ, et al. Epidemiological characteristics of ovarian cancer in Korea. J Gynecol Oncol. 2010;21(4):241-7.
3. Bast RC Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(Suppl 3):274-81. (Pubitemid 43096594)
4. Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006; 7(2):167-74. (Pubitemid 43159503)
5. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21(17):2768-73. (Pubitemid 34478335)
6. Berry NB, Cho YM, Harrington MA, et al. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol. 2004;92(3):896-904. (Pubitemid 38251394)
7. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65(6):2162-9. (Pubitemid 40490123)
8. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695-700. (Pubitemid 36793054)
9. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267-77. (Pubitemid 41502830)
10. Bingle L, Cross SS, High AS, et al. WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung. Respir Res. 2006;7:61.
11. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-8. (Pubitemid 351174295)
12. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6.
13. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315-9.
14. Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15-21.
15. Havrilesky LJ,Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110(3):374-82.
16. Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(9):2480-7.
17. Scholler N, Crawford M, Sato A, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006;12(7 Pt 1):2117-24.
18. Royston P. Multiple imputation of missing values. STATA J. 2004;4:227-41.
19. Harrell FE Jr., Lee KL,Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-87. (Pubitemid 26072233)
20. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5(12):e232.
21. Kamei M, Yamashita S, Tokuishi K, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res. 2010;30(11):4779-83.